Non-viral precision T cell receptor replacement for personalized cell therapy | Nature
FDA Panel Votes Unanimously to Support Leukemia Gene-Therapy Treatment - WSJ
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19 - Cytotherapy
ASH: Gilead, Novartis tout long-term data for CAR-T slow starters Yescarta, Kymriah | Fierce Pharma
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials: Molecular Therapy - Methods & Clinical Development
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas | Nature Medicine
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy | Nature Communications
ASCO: Positive trial shows Novartis' Kymriah poised to play catch-up in CAR- T rivalry with Gilead's Yescarta | Fierce Pharma
The Process of CAR-T Cell Therapy | Novartis
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell | Nature Medicine
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
NICE backs Novartis' Adakveo via special channel despite 'high uncertainty' about cost, long-term efficacy | Fierce Pharma
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials: Molecular Therapy - Methods & Clinical Development
Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma | Nature Communications
Frontiers | Manufacturing and Management of CAR T-Cell Therapy in “COVID-19's Time”: Central Versus Point of Care Proposals
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
Fred Hutch Statement Regarding FDA Briefing About CAR T-cell Therapy
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy | Nature Reviews Clinical Oncology
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
Novartis sidesteps Europe travel ban to provide CAR-T drug Kymriah to patients | Fierce Pharma
ASCO: Gilead's Kite soars over Novartis' CAR-T turf with Tecartus win in type of leukemia | Fierce Pharma
CAR T-cell treatment pathway: From patient identification to long-term management - touchONCOLOGY
